CD4+ cell counts
Significantly more people receiving lopinavir achieved viral suppression below 400 copies and 50 copies, though there were no differences between the two groups in the magnitude of CD4+ cell increases. There were no significant differences in side effects, including changes in triglyceride levels, between the two groups although fewer people receiving lopinavir discontinued drug primarily due to rebound in viral load (virological failure).
These results are not completely unexpected. Previous studies have shown lopinavir to have very potent activity against HIV, even among people who have previously received protease inhibitors. Additionally there have been concerns about the long-term potency of nelfinavir.
Back to the Project Inform Perspective March 2001 contents page.